NeoImmuneTech
Blood & Organ Banks · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2400 Research Blvd Ste 250, Rockville, M...Phone Number
(240) 801-9065Website
www.neoimmunetech.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
2
2
3
2
About NeoImmuneTech
Neoimmunetech specializes in enhancing immune cell proliferation and increasing tumor-infiltrating lymphocytes. The company focuses on the clonal expansion of T-cell receptors and inducing stem cell characteristics in T-cells. Their products and services aim to improve the efficacy of cancer treatments in conjunction with other modalities. Intended clients include healthcare providers and researchers in the oncology field.Explore more
NeoImmuneTech Org Chart
DK
Senior Manager, Operations
HH
Senior Manager
YB
Manager, Drug Safety
KS
Manager
JL
Manager
SI
Team Manager
WC
Manager
HP
Assistant Manager
WC
Assistant Manager
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeoImmuneTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NeoImmuneTech has new funding data
Product Launch: Get notified when NeoImmuneTech launches new products
Earning: See what the market has to say on NeoImmuneTech recently announced quarterly report
NeoImmuneTech, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if NeoImmuneTech had a recent Job posting/layoffs
Check out if NeoImmuneTech is spiking on competitors!
Check if NeoImmuneTech has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at NeoImmuneTech
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at NeoImmuneTech
Find more new buyers
Compare Similar Companies to NeoImmuneTech
Compare insights from companies similar to NeoImmuneTech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NeoImmuneTech is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
NeoImmuneTech is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about NeoImmuneTech.
NeoImmuneTech Tech Stack
A closer look at the technologies used by NeoImmuneTech
Most Recent Scoops
Hiring Plans
NeoImmuneTech has more open roles in Operations than it has had at any time in the past 12 months. Areas of expertise include: Logistics, Cross-Functional Collaboration, Warehouse Operations, and Supply Chain.
Hiring Plans
Person-Based
Open Position
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
NeoImmuneTech News & Media
EMA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
This regulatory milestone marks an acceleration of the process around NT-I7's potential first indication, after other recent positive news. NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS. ROCKVILLE, Md. , June 4, 2024...NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology
Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancer Correlative analysis identified potentially predictive protein biomarkers associated with...NeoImmuneTech's NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting
NT-I7 maintains cancer-specific T-cell amplifying efficacy when combined with standard of care colorectal cancer therapy FOLFOX® Study indicates interest for potential combination therapy with chemotherapeutic agents. ROCKVILLE, Md., April 9, 2024 /PRNewswire/ -- NeoImmuneTech, Inc....NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO) of NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), effective from March 29, 2024 (EDT). Having joined the...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeoImmuneTech
Sign Up For FreeTo access detailed company insights
Neoimmunetech specializes in enhancing immune cell proliferation and increasing tumor-infiltrating lymphocytes. The company focuses on the clonal expansion of T-cell receptors and inducing stem cell characteristics in T-cells. Their products and services aim to improve the efficacy of cancer treatments in conjunction with other modalities. Intended... Read More
